New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder

NCT ID NCT05397431

First seen Jun 24, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This study follows 155 people in Japan with hereditary angioedema (HAE) who are taking TAKHZYRO (lanadelumab) injections every two weeks. Researchers will monitor side effects and check if the drug helps control swelling attacks over 12 months. The goal is to see how well TAKHZYRO works in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Lanadelumab (TAKHZYRO)
What this could lead to
If successful, this study could confirm that TAKHZYRO is safe and effective for long-term use in controlling HAE attacks.
What could go wrong
This is an observational survey, not a controlled trial, so results may be less definitive. Side effects are still possible, and the study only includes Japanese participants, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Takeda selected site

    Tokyo, Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.